Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7182-7191

  Walker, Carol ^a   Du Plessis, Daniel G ^b   Fildes, Diane ^a   Haylock, Brian ^a   Husband, David ^a   Jenkinson, Michael D ^b   Joyce, Kathy A ^a   Broome, John ^b   Kopitski, Klaus ^b   Prosser, Joanne ^c   Smith, Trevor ^b   Vinjamuri, Sobhan ^c   Warnke, Peter C ^b  

^a CLATTERBRIDGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM EDETATE; GADOLINIUM PENTETATE; IOPROMIDE; THALLIUM 201;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; BRAIN BIOPSY; BRAIN METABOLISM; BRAIN TUMOR; CANCER RADIOTHERAPY; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIOTOMY; DRUG UPTAKE; FEMALE; GENOTYPE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MORPHOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTAXIC SURGERY; TUMOR DIAGNOSIS;

ADULT; AGED; ALLELES; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; LASERS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 8444228135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0681     Document Type: Article

References (67)

1. Rampling R. CRC Cancer Stats: brain and other central nervous system tumours-UK. CRC Cancer Stats: The Cancer Research Campaign London; 2000. p. 1-7.
2. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst (Bethesda) 1999;91:1382-90.
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
4. Caimcross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (Bethesda) 1998;90:1473-9.
5. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther 2001;1:348-56.
6. Perry JR, Caimcross JG. Glioma therapies: how to tell which work? J Clin Oncol 2003;21:3547-9.
7. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002;58:111-7;discussion 7.
8. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003;60:443-56.
9. Perry A. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 2001;8:183-99.
10. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25;discussion 26-9.
11. Perry JR. Oligodendrogliomas: clinical and genetic correlations. Curr Opin Neurol 2001;14:705-10.
12. Kleihues P, Cavanee W. Diffusely infiltrating astrocytomas. In: Kleihues P, Cavanee WK, editors. Pathology and genetics of tumors of the nervous system. Lyon: IARC Press; 2000. p.10-21.
13. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neurooncol 1999;1:52-60.
14. Ellis TL, Stieber VW, Austin RC. Oligodendroglioma. Curr Treat Options Oncol 2003;4:479-90.
15. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279-91;discussion 191.
16. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
17. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10.
18. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45.
19. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45.
20. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J Neuropathol Exp Neurol 2002;61:58-63.
21. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-5.
22. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-9.
23. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-104.
24. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 1998;39:440-8.
25. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37.
26. De Witte O, Lefranc F, Levivier M, et al. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 2000;49:157-63.
27. Higa T, Maetani S, Yoichiro K, Nabeshima S. TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med 2001;26:119-24.
28. Levivier M, Wikler D, Jr., Massager N, et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 2002;97:542-50.
29. Stokkel M, Stevens H, Taphoorn M, Van Rijk P. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201T1 SPET versus 18F-FDG PET using a dual-headed coincidence camera-a pilot study. Nucl Med Commun 1999;20:411-7.
30. Roesdi MF, Postma TJ, Hoekstra OS, et al. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998;40:251-5.
31. Vos MJ, Hoekstra OS, Barkhof F, et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 2003;21:3559-65.
32. Kallen K, Burtscher IM, Holtas S, Ryding E, Rosen I. 201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas. J Neurooncol 2000;46:173-85.
33. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 2002;8:971-9.
34. Brock CS, Young H, O'Reilly SM et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15.
35. Walker C, Joyce K, Du Plessis D, et al. Molecular genetic analysis of archival gliomas using diagnostic smears. Neuropathol Appl Neurobiol 2000;26:441-7.
36. Walker C, Joyce KA, Thompson-Hehir J, et al. Characterisation of molecular alterations in microdissected archival gliomas. Acta Neuropathol (Berl) 2001;101:321-33.
37. Walker C, du Plessis DG, Joyce KA, et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 2003;9:4841-51.
38. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003;33:148-62.
39. Kallen K, Heiling M, Andersson AM, et al. Preoperative grading of glioma malignancy with thallium-201 single-photon emission CT: comparison with conventional CT. AJNR Am J Neuroradiol 1996;17:925-32.
40. Kim KT, Black KL, Marciano D, et al. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med 1990;31:965-9.
41. Gungor F, Bezircioglu H, Guvenc G, et al. Correlation of thallium-201 uptake with proliferating cell nuclear antigen in brain tumours. Nucl Med Commun 2000;21:803-10.
42. Ishibashi M, Taguchi A, Sugita Y, et al. Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J Nucl Med 1995;36:2201-6.
43. Oriuchi N, Tamura M, Shibazaki T, et al. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 1993;34:2085-9.
44. Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method? Mol Imaging Biol 2003;5:281-5.
45. Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol 2003;5:257-70.
46. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802-8.
47. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459-62.
48. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79:853-8.
49. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269-71.
50. Derlon JM, Petit-Taboue MC, Chapon F, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 1997;40:276-87;discussion 87-8.
51. Maria BL, Drane WE, Mastin ST, Jimenez LA. Comparative value of thallium and glucose SPECT imaging in childhood brain tumors. Pediatr Neurol 1998;19:351-7.
52. Lamonica D, Grossman Z, Klippenstein D, et al. A comparative study of 511 keV SPECT and PET using separate 370 MBq F-18-FDG doses on different days. Clin Positron Imaging 1999;2:81-91.
53. Kam BL, Valkema R, Poldermans D, et al. Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration. J Nucl Med 2003;44:140-5.
54. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998;49:189-95; discussion 96.
55. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol 2000;50:99-108.
56. Tamura M, Shibasaki T, Zama A, et al. Assessment of malignancy of glioma by positron emission tomography with 18F-fluorodeoxyglucose and single photon emission computed tomography with thallium-201 chloride. Neuroradiology 1998;40:210-5.
57. Oriuchi N, Tomiyoshi K, Inoue T, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996;37:457-62.
58. Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261-9.
59. Woesler B, Kuwert T, Morgenroth C, et al. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 1997;24:428-34.
60. Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778-87.
61. Bissola L, Eoli M, Pollo B, et al. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 2002;52:842-5.
62. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol 2002;58:107-14.
63. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
64. Kuwert T, Woesler B, Morgenroth C, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998;39:23-7.
65. Warnke PC. Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy. J Neurosurg 1998;88:399A.
66. Warnke PC, Kopitzki K, Ostertag CB, S. Vinjamuri. The role of functional imaging in brain tumours. World J of Nucl Med 2003;2:37-44.
67. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J. Clin Oncol 1997;15:3423-6.